智通財經APP訊,復宏漢霖(02696)釋出公告,近日,一項比較公司自主開發的漢斯狀®(斯魯利單抗注射液)(漢斯狀®)或安慰劑分別聯合化療(卡鉑/順鉑-依託泊苷)同步放療用於治療侷限期小細胞肺癌(LS-SCLC)患者的國際多中心3 期臨床研...
HK) announced thatASTRUM-005, an international multi-centre study led by Professor Ying Cheng, has been published in The...
四種亞型特異性蛋白的免疫組化結果示例這五種小細胞肺癌亞型如下:SCLC-A亞型,表達ASCL1為主...